SciSparc Completes Production Of Its Dronabinol-Based Drug Candidate For Its Clinical Trial On Tourette Syndrome
SciSparc Ltd. (NASDAQ: SPRC) has successfully manufactured clinical batches of its drug candidate SCI-110 to be used in its upcoming multinational, multicenter, phase IIb trial for Tourette syndrome.
